Amgen AMGN, -2.85% has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases.
Wezlana was approved as a biosimilar to and interchangeable with Stelara for treating adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease and moderate to severely active ulcerative colitis.
The treatment is also approved for treating patients 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis. A biosimilar is a treatment that has no clinically meaningful difference from another treatment already approved by the FDA. headtopics.com
U.S. FDA approves Amgen’s biosimilar version of J&J’s psoriasis drugU.S. FDA approves Amgen’s biosimilar version of J&J’s psoriasis drug Read more ⮕
‘Hunger-Free November’: San Antonio Food Bank battles senior food insecurity with new initiativeTens of thousands of senior citizens in South Texas are struggling to make ends meet, which leads to food insecurity. Read more ⮕
San Francisco Ikea-adjacent food hall to feature five new food optionsAt the Ikea-adjacent San Francisco food hall set to open next spring, customers may be enjoying five Bay Area favorites like Curry Up Now and La Venganza. Read more ⮕
Fired fast-food worker still has a taste for the food: Bainbridge Township police blotterA Solon man made a scene in the parking lot of his former employer Oct. 17. A patron of the fast-food restaurant told employees inside that the agitated man was waving what appeared to be a gun. He left and police were informed of the incident the following day. The subject had been fired from his job there. Read more ⮕
Amgen third-quarter sales rise 5%; profit up before chargeAmgen third-quarter sales rise 5%; profit up before charge Read more ⮕
Amgen’s stock jumps premarket after earnings beat and company again raises guidanceCiara Linnane is MarketWatch’s investing- and corporate-news editor. She is based in New York. Read more ⮕